Ticker LaunchUplisting · CTDH
Cyclo Therapeutics, Inc.
Formerly CTD HOLDINGS INC; CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
Cyclo Therapeutics, Inc. (CTDH), already reporting to the SEC, moved up to Nasdaq Capital Market on Dec 11, 2020 with an offering at $5.00 per share raising $12.5M. Maxim Group was lead-left underwriter. Fox Rothschild advised the company.
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company developing cyclodextrin-based products. Its lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin), is being studied for Niemann-Pick Type C disease, a rare and fatal cholesterol metabolism disease affecting the brain, lungs, liver and spleen.
- Status
- Uplisting
- Ticker
- CTDH
- Exchange
- Nasdaq Capital Market
- Listed
- Dec 11, 2020
- Price
- $5.00
- Raised
- $12.5M
- Market cap at IPO price
- $21M
- First filed
- Jan 6, 2005
- Underwriters
- Maxim Group
- Company counsel
- Fox Rothschild
- Sector
- Biotech & pharma
- Country / state
- FL
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 6, 2005
- Latest amendment Dec 4, 2020
- Final prospectus (424B4) Dec 11, 2020
- All filings on EDGAR CIK 922247
Other Biotech & pharma uplistings in 2020
- Nomad Power Solutions, Inc.LIXT · Nov 27, 2020
- Processa Pharmaceuticals, Inc.PCSA · Oct 5, 2020 · $19.2M
- GeoVax Labs, Inc.GOVX · Sep 28, 2020 · $12.8M
- Biovie Inc.BIVI · Sep 18, 2020 · $15.7M
- Panbela Therapeutics, Inc.SNBP · Aug 31, 2020
- Windtree Therapeutics Inc /de/WINTD · May 21, 2020 · $20M